Completed PHASE4 INTERVENTIONAL 2-arm NCT01817322

Kidney Graft Function Under the Immunosuppression Strategies (MyLowCsA)

Kidney Graft Function Under the Immunosuppression Strategies With Low Dose of Neoral®(Cyclosporine) and Standard Dose of Myfortic®(Enteric-Coated Mycophenolate Sodium) vs. With Conventional Dose of Neoral®(Cyclosporine) and Reduced Dose of Myfortic®(Enteric-Coated Mycophenolate Sodium) in De Novo Renal Transplant Recipients

Sponsor: Samsung Medical Center

Conditions Chronic Renal Disease

Interventions Basiliximab injected both control group and experimental group Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group Standard Dose of Myfortic and Reduced Dose of Myfortic

Updated 5 times since 2017 Last updated: Oct 2, 2014 Started: Jun 30, 2011 Primary completion: Aug 31, 2013 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Chronic Renal Disease and is currently completed. Samsung Medical Center leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.